Epoch Investment Partners Inc. Has $725,000 Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Epoch Investment Partners Inc. lessened its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 63.7% during the 2nd quarter, HoldingsChannel reports. The fund owned 101,308 shares of the company’s stock after selling 178,124 shares during the period. Epoch Investment Partners Inc.’s holdings in Maravai LifeSciences were worth $725,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in MRVI. Frank Rimerman Advisors LLC acquired a new stake in shares of Maravai LifeSciences during the second quarter worth approximately $399,000. Symmetry Investments LP purchased a new position in shares of Maravai LifeSciences during the 2nd quarter valued at $823,000. Ensign Peak Advisors Inc acquired a new position in shares of Maravai LifeSciences in the second quarter worth $266,000. Thrivent Financial for Lutherans increased its stake in shares of Maravai LifeSciences by 6.8% in the second quarter. Thrivent Financial for Lutherans now owns 187,760 shares of the company’s stock worth $1,344,000 after acquiring an additional 11,874 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Maravai LifeSciences by 20.8% during the second quarter. Renaissance Technologies LLC now owns 3,881,441 shares of the company’s stock valued at $27,791,000 after purchasing an additional 668,552 shares during the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on MRVI shares. Morgan Stanley lowered Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $11.00 to $10.00 in a research report on Tuesday, August 13th. UBS Group increased their price objective on Maravai LifeSciences from $8.50 to $11.00 and gave the stock a “neutral” rating in a report on Thursday, August 8th. The Goldman Sachs Group raised their price objective on shares of Maravai LifeSciences from $7.00 to $8.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th. Royal Bank of Canada reissued an “outperform” rating and issued a $15.00 target price on shares of Maravai LifeSciences in a research report on Friday, August 16th. Finally, Wells Fargo & Company initiated coverage on shares of Maravai LifeSciences in a research note on Tuesday, August 27th. They set an “overweight” rating and a $10.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $10.78.

Maravai LifeSciences Trading Down 1.7 %

Shares of MRVI stock opened at $8.30 on Tuesday. Maravai LifeSciences Holdings, Inc. has a 12 month low of $4.52 and a 12 month high of $11.56. The company has a market cap of $2.09 billion, a PE ratio of -8.38 and a beta of 0.01. The company has a quick ratio of 9.28, a current ratio of 10.00 and a debt-to-equity ratio of 0.71. The business’s 50 day moving average is $8.89 and its two-hundred day moving average is $8.58.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $73.40 million for the quarter, compared to the consensus estimate of $71.64 million. Maravai LifeSciences had a negative return on equity of 4.78% and a negative net margin of 47.41%. Maravai LifeSciences’s quarterly revenue was up 6.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.06) earnings per share. Equities analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.17 EPS for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.